Clinical Trials on Non-communicable Disease in Belgium

Total 11222 results

Gilead Sciences

Completed

Efficacy and Safety Study of GS-9256 and GS-9190 Alone and in Combination With Ribavirin for 28 Days in Patients With Chronic Hepatitis C Virus Infection

HCV Infection

Germany, Belgium, United Kingdom, France
UMC Utrecht

Terminated

Prednisolone Addition for Patients With Recent-onset Psychotic Disorder

Schizophrenia | Schizoaffective Disorder | Schizophreniform Disorder | Psychotic Disorder NOS

Netherlands, Belgium, Denmark
Novartis Pharmaceuticals

Active, not recruiting

VOB560-MIK665 Combination First in Human Trial in Patients With Hematological Malignancies (Relapsed/Refractory Non-Hodgkin Lymphoma, Relapsed/Refractory Acute Myeloid Leukemia, or Relapsed/Refractory Multiple Myeloma)

Acute Myeloid Leukemia (AML) | Multiple Myeloma (MM) | Non-Hodgkin Lymphoma (NHL)

Belgium, Italy, Korea, Republic of, Hong Kong, Israel, Finland, Spain, Japan, United States
Regeneron Pharmaceuticals
Sanofi

Terminated

A Study of REGN2810 and Ipilimumab in Patients With Lung Cancer

Advanced Non-Small Cell Lung Carcinoma

United States, Belgium, France, Germany, Korea, Republic of, Poland, Spain, Taiwan, United Kingdom
Sanofi

Active, not recruiting

Tusamitamab Ravtansine in NSQ NSCLC Participants With Negative or Moderate CEACAM5 Expression Tumors and High Circulating CEA (CARMEN-LC06)

Non-squamous Non-small Cell Lung Cancer

Belgium, Italy, Spain, Japan, United States, France, Turkey
Janssen R&D Ireland

Completed

A Study to Evaluate the Safety, Tolerability, and Effectiveness of a 12-Week Combination Therapy of TMC647055 and TMC435 With and Without GSK23336805 With a Pharmacokinetic Enhancer With and Without Ribavirin in Patients Infected With Chronic Genotype 1 Hepatitis C Virus

Chronic Hepatitis C

Belgium, Germany
Amgen

Completed

Study to Evaluate Safety and Efficacy of Blinatumomab in Subjects With Relapsed/Refractory (R/R) Aggressive B-Cell NHL

B-Cell Non Hodgkin Lymphoma

United States, Spain, United Kingdom, Belgium, Italy, Australia, Canada, Puerto Rico
Novartis Pharmaceuticals

Terminated

PDR001 in Combination With Platinum-doublet Chemotherapy and Other Immunology Agents in PD-L1 Unselected, Metastatic NSCLC Patients

Non-small Cell Lung Cancer

France, Spain, United States, Belgium, Netherlands, Canada, Italy, Singapore, Korea, Republic of, Czechia, Germany, Hong Kong
Hoffmann-La Roche

Recruiting

A Dose Escalation Study of Glofitamab (RO7082859) as a Single Agent and in Combination With Obinutuzumab, Administered After a Fixed, Single Pre-Treatment Dose of Obinutuzumab in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Non-Hodgkin's Lymphoma

Belgium, Australia, Denmark, Spain, Taiwan, France, Italy, United States, Canada, Czechia, New Zealand, Poland, Finland
Hoffmann-La Roche

Recruiting

A Study to Evaluate the Safety, Pharmacokinetics and Preliminary Anti-Tumor Activity of RO7227166 in Combination With Obinutuzumab and in Combination With Glofitamab Following a Pre-Treatment Dose of Obinutuzumab Administered in Participants With Relapsed/Refractory B-Cell Non-Hodgkin's Lymphoma

Lymphoma, Non-Hodgkin

United States, Belgium, Australia, Denmark, Italy, Spain, France, United Kingdom
Cochlear

Completed

Innovations in Clinical Care of CE Approved Nucleus Cochlear Implant Recipients

Hearing Loss

Belgium, Australia
Tibotec Pharmaceuticals, Ireland

Completed

A Study to Assess the Anti-viral Activity, Safety, Tolerability and Pharmacokinetics of TMC435350 in Participants Infected With Hepatitis C-Virus (HCV)

Hepatitis C

Belgium, Germany, Thailand
Theravectys S.A.

Completed

Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).

HIV Infection

France, Belgium
Oslo University Hospital
Institut National de la Santé Et de la Recherche Médicale, France; Epidemiological...

Terminated

EU SolidAct: An Adaptive Pandemic and Emerging Infection Platform Trial (Bari-SolidAct)

COVID-19 | Emerging Infectious Disease

Spain, Belgium, France, Norway, Ireland, Luxembourg, Greece, Slovakia, Hungary, Portugal, Austria, Czechia, Germany, Italy, Turkey
GlaxoSmithKline

Completed

Study to Show That the Combined Hepatitis A and B Vaccine is Non-inferior to Monovalent Vaccines in Adults

Hepatitis B | Hepatitis A

Germany, Belgium
Celgene

Terminated

A Phase II Study of Single-Agent Lenalidomide in Subjects With Relapsed Or Refractory T-Cell Non-Hodgkin's Lymphoma (EXPECT)

T-cell Non-Hodgkin's Lymphoma

France, United States, Australia, Belgium
Gilead Sciences

Completed

Open Label Study of Pharmacokinetics and Safety of Dose of Adefovir Dipivoxil in Children and Adolescents With HBV

Hepatitis B

Belgium, Germany, Poland, United Kingdom
Janssen Vaccines & Prevention B.V.
Bavarian Nordic

Terminated

Safety, Reactogenicity and Immunogenicity of Adenovirus Serotype 26 (Ad26)- and Modified Vaccinia Ankara (MVA)-Vectored Vaccine Components in Otherwise Healthy Women With HPV16 or HPV18 Infection of the Cervix

Human Papillomavirus Infections

United States, Belgium
Novartis Pharmaceuticals

Active, not recruiting

Study of Safety and Efficacy of Ceritinib in Combination With Nivolumab in Patients With ALK-positive Non-small Cell Lung Cancer

ALK-positive NSCLC

Belgium, Spain, Italy, Australia, United States, Hong Kong, Canada, Singapore
European Organisation for Research and Treatment...

Terminated

Gefitinib After Chemotherapy in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer

Lung Cancer

Italy, Netherlands, Egypt, Belgium, Cyprus
Amgen

Completed

Study of Talimogene Laherparepvec In Children With Advanced Non CNS Tumors

Advanced Non CNS Tumors

United States, Belgium, Spain, France, Canada, Italy, Switzerland
Novartis Pharmaceuticals

Completed

Pharmacokinetics and Safety of Single-Dose Telbivudine in Children and Adolescents With Chronic Hepatitis B

Chronic Hepatitis B

Belgium, Germany, United Kingdom, Philippines
Synta Pharmaceuticals Corp.

Terminated

Study of Ganetespib (STA-9090) + Docetaxel in Advanced Non Small Cell Lung Cancer (GALAXY)

Non-small Cell Lung Cancer Metastatic | Non-small Cell Lung Cancer Stage IIIB | Non-small Cell Lung Cancer Stage IV

United States, Belgium, Bosnia and Herzegovina, Canada, Croatia, Czech Republic, Germany, Poland, Romania, Russian Federation, Serbia, Spain, United Kingdom
Universitair Ziekenhuis Brussel
Kom Op Tegen Kanker; Agentschap voor Innovatie door Wetenschap en Technologie...

Recruiting

Repeatability of 68-GaNOTA-Anti-HER2 VHH1 PET/CT in Breast Carcinoma Patients (VUBAR)

Gastric Cancer | Colorectal Cancer | Prostate Cancer | Non Small Cell Lung Cancer | Cholangiocarcinoma | Endometrial Cancer | Urothelial Carcinoma | Biliary Tract Cancer | Locally Advanced Breast Cancer | Cancer of Pancreas | Uterine Cancer | Salivary Gland Cancer | Metastatic Breast Carcinoma | Solid Tumor With Intermediate...

Belgium
Jules Bordet Institute
Merck KGaA, Darmstadt, Germany

Active, not recruiting

Avelumab as Neoadjuvant Therapy in Subjects With Urothelial Muscle Invasive Bladder Cancers (AURA Trial) (AURA)

Non-metastatic Muscle Invasive Bladder Cancer

France, Belgium
Kite, A Gilead Company

Active, not recruiting

Study Evaluating Brexucabtagene Autoleucel (KTE-X19) in Pediatric and Adolescent Participants With Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia or Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (ZUMA-4)

Relapsed/Refractory B-precursor Acute Lymphoblastic Leukemia | Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma

Spain, United States, Czechia, Sweden, Germany, Belgium, Italy, Canada, France, Netherlands, Poland
AstraZeneca

Completed

Study to Describe Treatment Patterns and Outcomes in EGFRm NSCLC Patients in Belgium (REVEAL)

Carcinoma, Non-Small-Cell Lung

Belgium
AstraZeneca

Active, not recruiting

A Study of Novel Anti-cancer Agents in Patients With Previously Untreated NSCLC (MAGELLAN)

Metastatic Non-Small Cell Lung Cancer (NSCLC)

United States, Spain, Belgium, Poland, Taiwan, Thailand, Korea, Republic of, Russian Federation, Austria
Centre Hospitalier Departemental Vendee

Completed

Evaluation of the Strip PeriScreen for the Fast Diagnosis of the Spontaneous Infection of the Liquid of Ascites During the Cirrhosis (Per-DRISLA)

Cirrhosis | Infection | Liquid of Ascites

France, Belgium
ExThera Medical Europe BV
ExThera Medical Corporation; Vivantes Clinic Neukölln

Recruiting

Reduction of Pathogen Load From the Blood in Septic Patients With Suspected, Life-threatening Bloodstream Infection

Bloodstream Infection

France, Germany, Netherlands, Austria, Belgium, Italy, Poland, Spain, United Kingdom
Novartis Pharmaceuticals

Completed

A Safety and Efficacy Study of INC280 and Gefitinib in Patients With EGFR Mutated, c-MET-amplified NSCLC Who Have Progressed After EGFRi Treatment

Non-small Cell Lung Cancer

China, Taiwan, Belgium, Netherlands, Spain, Germany, Singapore, Italy, Japan, Australia, Israel, Korea, Republic of, Thailand, France
Boehringer Ingelheim

Completed

A Study to Test Safety and Efficacy of BI456906 in Adults With Non-alcoholic Steatohepatitis (NASH) and Fibrosis (F1-F3)

Non-alcoholic Steatohepatitis (NASH)

United States, Spain, Korea, Republic of, United Kingdom, Australia, Canada, Singapore, Germany, Italy, Malaysia, China, France, Japan, Taiwan, Netherlands, Austria, Israel, New Zealand, Poland, Hong Kong, Belgium, Czechia, Greece, Hu... and more
AstraZeneca

Active, not recruiting

A Study of AZD2936 Anti-TIGIT/Anti-PD-1 Bispecific Antibody in Participants With Advanced or Metastatic NSCLC (ARTEMIDE-01)

Non-Small-Cell Lung Carcinoma

France, Spain, Thailand, Belgium, Korea, Republic of, Netherlands, United States, Brazil, Japan, China, Malaysia, Taiwan, Australia, Denmark
Novartis Pharmaceuticals

Terminated

This Study Will Evaluate the Effect of Canakinumab or Pembrolizumab Given as Monotherapy or in Combination as Neo-adjuvant Treatment for Subjects With Early Stages NSCLC. (CANOPY-N)

Non-small Cell Lung Cancer

Canada, Netherlands, Spain, France, Japan, Russian Federation, Germany, Belgium, Greece, Turkey, Taiwan, United States
Bristol-Myers Squibb

Terminated

Study of BMS-275183 in Patients With Pretreated Locally Advanced or Metastatic NSCLC (Non Small Cell Lung Cancer)

Non-small Cell Lung Cancer

Spain, Belgium, France, Italy, Netherlands, Canada, United Kingdom, United States
Lymphoma Study Association
Amgen

Completed

ACVBP Plus Rituximab Versus CHOP Plus Rituximab in Patients With Diffuse Large B-cell Lymphoma and Age-adjusted IPI of 1

Diffuse Large-Cell Lymphoma

France, Belgium
Cephalon

Completed

Study to Evaluate the Efficacy and Safety of Treatment With Bendamustine in Combination With Ofatumumab in Previously Untreated Patients With Indolent B-Cell Non-Hodgkin's Lymphoma (NHL)

Non-Hodgkin's Lymphoma (NHL)

United States, Belgium, Israel
Lymphoma Study Association
Fondation ARC

Terminated

R-ACVBP Versus R-CHOP in Patients Aged 60-65 With Diffuse Large B-cell Lymphoma

Lymphoma, Large-Cell, Diffuse

France, Switzerland, Belgium
Eli Lilly and Company
Merck Sharp & Dohme LLC

Active, not recruiting

A Study of Abemaciclib (LY2835219) in Participants With Non-Small Cell Lung Cancer or Breast Cancer

Breast Cancer | Non Small Cell Lung Cancer

United States, Spain, France, Belgium, Italy, Taiwan, Turkey
Eli Lilly and Company

Completed

Study of LY2181308 in Combination With Docetaxel Versus Docetaxel in Patients With Non-Small Cell Lung Cancer

Non-small Cell Lung Cancer

Italy, United States, Germany, Poland, Belgium, United Kingdom
Verastem, Inc.
Amgen

Recruiting

Phase 1/2 Study of Avutometinib (VS-6766) + Sotorasib With or Without Defactinib in KRAS G12C NSCLC Patients (RAMP203)

Non Small Cell Lung Cancer | KRAS Activating Mutation

United States, Spain, France, United Kingdom, Netherlands, Belgium
Bristol-Myers Squibb
Eli Lilly and Company; Clovis Oncology, Inc.; Exelixis

Withdrawn

A Clinical Study Evaluating Nivolumab-containing Treatments in Patients With Advanced Non-small Cell Lung Cancer After Failing Previous PD-1/(L)1 Therapy and Chemotherapy (CheckMate 79X)

Carcinoma, Non-small Cell Lung Cancer

Netherlands, Norway, Belgium, Greece, United States, Argentina, Denmark, Mexico, Poland, Romania
Novartis Pharmaceuticals
Allergan

Completed

Study of Safety, Tolerability, and Efficacy of a Combination Treatment of LJN452 and CVC in Adult Patients With NASH and Liver Fibrosis (TANDEM)

Non-alcoholic Steatohepatitis (NASH)

United States, Belgium, Spain, Canada, Argentina, Israel, Germany, France, Italy, Turkey, Singapore, Russian Federation, United Kingdom, Czechia, Egypt, India, Latvia
Universitaire Ziekenhuizen KU Leuven

Unknown

Serological Testing for COVID-19 (SARS-CoV-2) in ESKD

SARS-CoV 2 | End Stage Renal Failure on Dialysis

Belgium
GlaxoSmithKline

Completed

Effect of Risk Factors Likely to Influence Immuno of Combined Hepatitis A & B Vacc vs Monovalent Hepatitis A & B Vacc

Hepatitis B | Hepatitis A

Germany, Belgium, Czechia
Barinthus Biotherapeutics

Completed

Prime-boost Vaccine Study in Women With Low-grade Cervical HPV Lesions

HPV Infection | CIN1

Belgium, United Kingdom, Estonia
The Lymphoma Academic Research Organisation
Janssen Pharmaceutica N.V., Belgium

Terminated

Bruton's Tyrosine Kinase (BTK) Inhibition in B-cell Lymphomas (BIBLOS)

B-cell Lymphoma

France, Belgium
GlaxoSmithKline

Completed

Long Term Follow-up Study at Years 2, 3, 4 and 5 Where 2 Dosing Schedules of the Combined Hepatitis A and B Vaccine Were Compared

Hepatitis B | Hepatitis A

Australia, Belgium, Spain
Bristol-Myers Squibb
PENTA Foundation

Completed

Post-marketing Safety Surveillance Program in Human Immunodeficiency Virus (HIV)-Infected Children Exposed to Atazanavir in Europe

HIV Infection

Romania, Belgium, Germany, Italy, Spain, Switzerland, United Kingdom
Instituto Ecuatoriano de Enfermedades Digestivas
University of Sao Paulo; Universitair Ziekenhuis Brussel; The Methodist Hospital... and other collaborators

Completed

Artificial Intelligence for Digital Cholangioscopy Neoplasia Diagnosis

Common Bile Duct Neoplasms | Non-Neoplastic Bile Duct Disorder

United States, Ecuador, Belgium, Brazil

Clinical Trials on Non-communicable Disease in Belgium

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Slovakia

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations